Immune-related adverse events are commonly observed following CTLA-4 inhibition in melanoma treatment, and a spectrum of these conditions are also observed in individuals with germline haploinsufficiency of <i>CTLA4</i>. The gene discussed is CTLA4; the disease is melanoma.